Atara Biotherapeutics Inc. (ATRA) carries a Roarable Rating of D (Sell) with 49/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-03, Atara Biotherapeutics Inc. (NASDAQ: ATRA) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 49/100 at a spot price of $8.01 (-6.10% 1D, market cap $80.4M). Pillar breakdown: Fundamental Cash Engine 11/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 8/20. Across 1016 tracked Health Care issuers, ATRA ranks #281 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), ATRA carries a Roarable D (49/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of 85.0%. By comparison, TNYA (Tenaya Therapeutics Inc.) holds a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $83.7M) and OKYO (OKYO Pharma Limited) posts a D grade (49/100 RQD, P/E N/A, ROIC —, cap $77.1M). Among the 5-stock peer group, ATRA leads on earnings multiple (N/A) while ATRA leads on capital efficiency (85.0% ROIC).
Per ATRA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001604464), Atara Biotherapeutics Inc. generated $120.8M in revenue (-6.3% YoY), $32.7M in net income, and -$50.9M in free cash flow against $20.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
FRED Regime × Technicals: 27% of 52W Range • RSI-14 at 37.5 (NEUTRAL RANGE)
SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin
Put hedging (50% put share) caps near-term gamma upside (-15 pts vs max)
While ATRA currently carries a cautious 49/100 (D) rating due to Whale & Options Positioning (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($9.16) and Max Pain ($8.41) forces dealer call-delta covering toward $20.11.
Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.12% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Atara Biotherapeutics Inc. (ATRA) dropped -6.10% to $8.01, trading at 27% of its 52-week range ($3.92 – $19.15). Stretched risk/reward at current multiples (85% return on capital) under elevated 10-year interest-rate pressure.
Yahoo Finance report covering Atara Biotherapeutics Inc. (ATRA) market action, institutional positioning, and fundamental catalysts.
kalkine.ca report covering Atara Biotherapeutics Inc. (ATRA) market action, institutional positioning, and fundamental catalysts.
https://www.siam.in/ report covering Atara Biotherapeutics Inc. (ATRA) market action, institutional positioning, and fundamental catalysts.
Investing.com UK report covering Atara Biotherapeutics Inc. (ATRA) market action, institutional positioning, and fundamental catalysts.
Stock Traders Daily report covering Atara Biotherapeutics Inc. (ATRA) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance Singapore report covering Atara Biotherapeutics Inc. (ATRA) market action, institutional positioning, and fundamental catalysts.
Yahoo! Finance Canada report covering Atara Biotherapeutics Inc. (ATRA) market action, institutional positioning, and fundamental catalysts.
https://www.dars.gov.et/ report covering Atara Biotherapeutics Inc. (ATRA) market action, institutional positioning, and fundamental catalysts.
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. -6.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on ATRA today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for ATRA. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Atara Biotherapeutics Inc. (ATRA) ranks #281 by composite RQD confidence (49/100, grade D) and #682 by equity capitalization ($80.4M). Within this direct 5-issuer industry benchmark cohort, ATRA leads on earnings valuation at N/A trailing P/E, while ATRA leads on capital efficiency and profitability with 85.0% ROIC and — gross margin. ATRA currently leads its immediate peer cohort in composite quantitative strength at 49/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| ATRA
ACTIVE
Atara Biotherapeutics Inc. | D | 49/100 | — | — | 85.0% | -6.10% | $80.4M | Benchmark Subject |
| TNYA Tenaya Therapeutics Inc. | D- | 40/100 | — | — | -35.0% | -7.78% | $83.7M | /tnya-vs-atra → |
| OKYO OKYO Pharma Limited | D | 49/100 | — | — | — | -2.00% | $77.1M | /okyo-vs-atra → |
| TVGN Tevogen Inc. | E | 30/100 | — | — | -35.0% | -2.48% | $92.8M | /tvgn-vs-atra → |
| CRDF Cardiff Oncology Inc. | E | 25/100 | — | — | -35.0% | -2.46% | $69.2M | /crdf-vs-atra → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Atara Biotherapeutics Inc. (ATRA) reported GAAP revenue of $120.8M (-6.3% vs. FY2024 revenue of $128.9M , and +1308.7% cumulative change since FY2023) , GAAP net income of $32.7M, operating cash flow of -$50.9M, and free cash flow of -$50.9M (+26.1% YoY). On the balance sheet, ATRA closed FY2025 with $20.2M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $120.8M | $32.7M | -$50.9M | -$50.9M | $20.2M | — |
| FY2024 (FY) | 2024-12-31 | $128.9M | -$85.4M | -$68.7M | -$69.0M | $109.1M | — |
| FY2023 (FY) | 2023-12-31 | $8.6M | -$276.1M | -$193.0M | -$193.0M | — | — |
As of 2026-11-03, Atara Biotherapeutics Inc. (NASDAQ: ATRA) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 49/100 at a spot price of $8.01 (-6.10% 1D, market cap $80.4M). Pillar breakdown: Fundamental Cash Engine 11/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 8/20. Across 1016 tracked Health Care issuers, ATRA ranks #281 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), ATRA carries a Roarable D (49/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of 85.0%. By comparison, TNYA (Tenaya Therapeutics Inc.) holds a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $83.7M) and OKYO (OKYO Pharma Limited) posts a D grade (49/100 RQD, P/E N/A, ROIC —, cap $77.1M). Among the 5-stock peer group, ATRA leads on earnings multiple (N/A) while ATRA leads on capital efficiency (85.0% ROIC).
Per ATRA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001604464), Atara Biotherapeutics Inc. generated $120.8M in revenue (-6.3% YoY), $32.7M in net income, and -$50.9M in free cash flow against $20.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
ATRA last traded at $8.01 (-6.10% on volume of 29,968 shares), positioning the stock -12.55% below its 50-day simple moving average ($9.16) and +4.03% above its 200-day simple moving average ($7.70). Across its 52-week range of $3.92 to $19.15, ATRA sits at the 26.9% percentile with a 14-day RSI of 37.5 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($7.01 to $9.01).
Why ATRA Stock dropped -6.10% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (85% return on capital) under elevated 10-year interest-rate pressure.
The Roarable RQD Score is 54, graded D+, with the verdict "Roarable Sell — Weak Fundamentals / Trim," per the Roarable RQD rating. The five pillars are:
For a prospective investor, the rating points to a weak overall profile. The strongest pillar (Macro Regime Fit) is driven by a beta of 1.0 rather than by business strength, while the Fundamental Cash Engine is held back by zero free-cash-flow yield despite a headline ROIC of 85%. The gap between reported operating/net margins and negative free cash flow is the central tension to examine: earnings-based metrics and cash-based metrics are pointing in different directions. Valuation tradeoffs cannot be fully assessed because P/E, forward P/E, EV/EBITDA, and EPS are not available in source data. This brief is educational and does not constitute personalized financial advice.
Atara Biotherapeutics Inc. (ATRA) is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Biological Products (No Diagnostic Substances) industry, per the company profile. The source data does not describe its products, customers, or revenue model in detail. The profile identifies a market capitalization of $0.1B. Recent news references a resubmitted Tabelecleucel (Tab-cel®) Biologics License Application accepted by the U.S. Food and Drug Administration, per the recent news section.
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $120.8M | $35.9M | $32.7M | N/A | $-50.9M | $8.5M | N/A |
| FY 2024 | $128.9M | $-83.4M | $-85.4M | N/A | $-69.0M | $25.0M | N/A |
| FY 2023 | $8.6M | $-276.0M | $-276.1M | N/A | $-193.0M | N/A | N/A |
Per the SEC financials, FY 2025 shows positive operating income of $35.9M and net income of $32.7M, while free cash flow was $-50.9M. Per the Snapshot data, operating margin is 29.7% and net margin is 27.1%, with gross margin at 0%. Per the RQD rating, the Altman Z-Score is 2.5, the Piotroski F-Score is 3/9, and Debt/Equity is 0.5. Cash declined from $25.0M in FY 2024 to $8.5M in FY 2025 per the SEC financials, and the balance sheet posture should be read alongside the negative free cash flow in each reported year.
Real-time company headlines, analyst actions, and sector developments for Atara Biotherapeutics Inc. (ATRA) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo Finance report covering Atara Biotherapeutics Inc. (ATRA) market action, institutional positioning, and fundamental catalysts.
kalkine.ca report covering Atara Biotherapeutics Inc. (ATRA) market action, institutional positioning, and fundamental catalysts.
https://www.siam.in/ report covering Atara Biotherapeutics Inc. (ATRA) market action, institutional positioning, and fundamental catalysts.
Investing.com UK report covering Atara Biotherapeutics Inc. (ATRA) market action, institutional positioning, and fundamental catalysts.
Stock Traders Daily report covering Atara Biotherapeutics Inc. (ATRA) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance Singapore report covering Atara Biotherapeutics Inc. (ATRA) market action, institutional positioning, and fundamental catalysts.
Yahoo! Finance Canada report covering Atara Biotherapeutics Inc. (ATRA) market action, institutional positioning, and fundamental catalysts.
https://www.dars.gov.et/ report covering Atara Biotherapeutics Inc. (ATRA) market action, institutional positioning, and fundamental catalysts.
Welcome to the ATRA (Atara Biotherapeutics Inc.) Roar Pit. Current RQD Composite is 54/100 (Roarable Sell — Weak Fundamentals / Trim) in Biotechnology: Biological Products (No Diagnostic Substances). Bulls point to capital efficiency (85.0% ROIC), while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
Everyone in here is repeating the bull case on ATRA, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Atara Biotherapeutics Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
Looking at the 5-pillar RQD breakdown on ATRA, the market is fixating on short-term headline noise in Biotechnology: Biological Products (No Diagnostic Substances) and ignoring the balance sheet and cash flow trajectory. At $8.01 (52-wk range $3.92 - $19.15), any beat on forward guidance forces shorts and underweight funds to chase.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).